Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Azithromycin in viral infections
Madeleine Oliver, Timothy S.C. Hinks
Reviews in Medical Virology (2020) Vol. 31, Iss. 2
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 605-612
Open Access | Times Cited: 531
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Christopher Butler, Jienchi Dorward, Ly‐Mee Yu, et al.
The Lancet (2021) Vol. 397, Iss. 10279, pp. 1063-1074
Open Access | Times Cited: 272
The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 150
Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection
Catherine E. Oldenburg, Benjamin A. Pinsky, Jessica Brogdon, et al.
JAMA (2021) Vol. 326, Iss. 6, pp. 490-490
Open Access | Times Cited: 116
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
Timothy S.C. Hinks, Lucy Cureton, Ruth Knight, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 10, pp. 1130-1140
Open Access | Times Cited: 79
The immunomodulatory effects of macrolide antibiotics in respiratory disease
Jennifer S. Pollock, James D. Chalmers
Pulmonary Pharmacology & Therapeutics (2021) Vol. 71, pp. 102095-102095
Open Access | Times Cited: 79
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development
Jennifer Kricker, Clive P. Page, Fridrik Runar Gardarsson, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 4, pp. 1404-1433
Open Access | Times Cited: 57
What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms
Sawsan Aboul‐Fotouh, Ahmed N. Mahmoud, Esraa M. Elnahas, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 29
COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa
Bisi Bright, Chinedum P. Babalola, Nadia A. Sam‐Agudu, et al.
Globalization and Health (2021) Vol. 17, Iss. 1
Open Access | Times Cited: 50
An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
Sayer Al‐Azzam, Nizar M. Mhaidat, Hayaa Abdallah Banat, et al.
Antibiotics (2021) Vol. 10, Iss. 6, pp. 690-690
Open Access | Times Cited: 46
Brief review on repurposed drugs and vaccines for possible treatment of COVID-19
Priyasha De, Ishita Chakraborty, Bhargavi Karna, et al.
European Journal of Pharmacology (2021) Vol. 898, pp. 173977-173977
Open Access | Times Cited: 42
Azithromycin through the Lens of the COVID-19 Treatment
Georgia G. Kournoutou, George P. Dinos
Antibiotics (2022) Vol. 11, Iss. 8, pp. 1063-1063
Open Access | Times Cited: 33
A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable
William Cookson, Miriam F. Moffatt, Garth Rapeport, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 205, Iss. 11, pp. 1271-1280
Open Access | Times Cited: 30
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
Elisa Souza Vaz, Sandra V. Vassiliades, Jeanine Giarolla, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 6, pp. 723-751
Open Access | Times Cited: 16
A one-two punch strategy for diabetic wound management based on an antibiotic-hybrid biomineralized iron sulfide nanoparticle
Shuangpiao Deng, Kaixin Ou, Chen‐Yu Zhang, et al.
Acta Biomaterialia (2024) Vol. 181, pp. 333-346
Closed Access | Times Cited: 6
Pathological and pharmacovigilance monitoring as toxicological imputations of azithromycin and its residues in broilers
Ahmed Fotouh, Doaa Safwat Abdel-Maguid, Maha Abdelhaseib, et al.
Veterinary World (2024), pp. 1271-1280
Open Access | Times Cited: 5
Therapeutic Management of Ebola Virus: Targeting Oxidative Stress and Inflammatory Pathways
Martin Ndayambaje, Hicham Wahnou, Abdallah Naya, et al.
BioChem (2025) Vol. 5, Iss. 1, pp. 3-3
Open Access
National trends in Azithromycin consumption during 2017–2023 in Kazakhstan: impact of the COVID-19 pandemic and the imperative for enhanced clinical guidelines
Laura Kassym, Assiya Kussainova, Д. В. Семенов, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
The Protective Role of Folic Acid in Biochemical and Histopathological Changes Induced by Azithromycin in the Livers of Pregnant Albino Rats
Safaa M. Hanafy, Soha S. Zakaria
Medicina (2025) Vol. 61, Iss. 3, pp. 415-415
Open Access
Therapeutic effect of pH responsive Magainin II modified azithromycin plus curcumin micelles in different depth models of MRSA infection
Lu Zhang, Rui-bo Guo, Liu Yang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Antibiotic prescription in pediatric patients with influenza in outpatient and emergency departments: A cross-sectional study
Yanan Li, Xiaolu Nie, Yu‐Chuan Li, et al.
Journal of Infection and Public Health (2025) Vol. 18, Iss. 6, pp. 102730-102730
Open Access
Sustained Azithromycin Release via Hydroxyapatite-Polylactic Acid Composite Microspheres
Shivi Tripathi, Harpreet Singh, Himansu Sekhar Nanda
Mechanisms and machine science (2025), pp. 397-412
Closed Access
Integration of 3D-printed micromixers and spray drying for pulmonary delivery of antimicrobial microparticles
Brayan J. Anaya, Aytug Kara, Rafaela Raposo, et al.
International Journal of Pharmaceutics (2025), pp. 125493-125493
Closed Access
Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery
Chen Yao, Meixiu Li, Guo‐Dong Lu, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 6, pp. 1538-1546
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top